PE20221168A1 - Agonistas del receptor npy2 - Google Patents
Agonistas del receptor npy2Info
- Publication number
- PE20221168A1 PE20221168A1 PE2022000757A PE2022000757A PE20221168A1 PE 20221168 A1 PE20221168 A1 PE 20221168A1 PE 2022000757 A PE2022000757 A PE 2022000757A PE 2022000757 A PE2022000757 A PE 2022000757A PE 20221168 A1 PE20221168 A1 PE 20221168A1
- Authority
- PE
- Peru
- Prior art keywords
- analogs
- obesity
- prevention
- pyy
- receptor agonists
- Prior art date
Links
- 102000029748 Neuropeptide Y2 receptor Human genes 0.000 title 1
- 108010089579 neuropeptide Y2 receptor Proteins 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 208000008589 Obesity Diseases 0.000 abstract 2
- 230000037396 body weight Effects 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 235000020824 obesity Nutrition 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2271—Neuropeptide Y
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Esta referido a analogos de PYY que tienen alanina en la posicion 4, lisina en la posicion 7, QRY como el extremo del terminal C y un grupo de prolongacion de semivida. Los analogos de la invencion son solubles a alrededor de pH 6 y 7. La invencion tambien se refiere a composiciones farmaceuticas que comprenden tales analogos de PYY y al uso medico de los analogos. Estos compuestos se emplean en el tratamiento y/o la prevencion de una variedad de enfermedades, tales como el tratamiento y/o la prevencion de la ingesta excesiva de alimentos, exceso de peso corporal, obesidad, enfermedades metabolicas y otras afecciones o trastornos relacionados con el exceso de peso corporal o la obesidad, por ejemplo, diabetes y enfermedades cardiovasculares.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19208394 | 2019-11-11 | ||
| PCT/EP2020/081513 WO2021094259A1 (en) | 2019-11-11 | 2020-11-09 | Npy2 receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20221168A1 true PE20221168A1 (es) | 2022-07-25 |
Family
ID=68531488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022000757A PE20221168A1 (es) | 2019-11-11 | 2020-11-09 | Agonistas del receptor npy2 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20210139548A1 (es) |
| EP (1) | EP4058047A1 (es) |
| JP (1) | JP2023500895A (es) |
| KR (1) | KR20220100925A (es) |
| CN (1) | CN114641303A (es) |
| AR (1) | AR120440A1 (es) |
| AU (1) | AU2020384729A1 (es) |
| CA (1) | CA3156452A1 (es) |
| CL (1) | CL2022001227A1 (es) |
| CO (1) | CO2022006046A2 (es) |
| CR (1) | CR20220206A (es) |
| DO (1) | DOP2022000097A (es) |
| EC (1) | ECSP22037660A (es) |
| IL (1) | IL292601A (es) |
| JO (1) | JOP20220110A1 (es) |
| MX (1) | MX2022005661A (es) |
| PE (1) | PE20221168A1 (es) |
| PH (1) | PH12022551101A1 (es) |
| TW (1) | TWI864155B (es) |
| WO (1) | WO2021094259A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3156452A1 (en) | 2019-11-11 | 2021-05-20 | Boehringer Ingelheim International Gmbh | Npy2 receptor agonists |
| CN116171282A (zh) * | 2020-08-07 | 2023-05-26 | 勃林格殷格翰国际有限公司 | 可溶npy2受体激动剂 |
| EP4572782A1 (en) | 2022-08-18 | 2025-06-25 | Boehringer Ingelheim International GmbH | Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists |
| TW202438512A (zh) * | 2022-12-21 | 2024-10-01 | 德商百靈佳殷格翰國際股份有限公司 | Glp1/gip/npy2受體之三重促效劑 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1961000B (zh) | 2004-02-11 | 2011-05-04 | 安米林药品公司 | 具有可选择特性的杂合多肽 |
| MXPA06010347A (es) | 2004-03-17 | 2007-06-19 | 7Tm Pharma As | Agonistas de receptor selectivo de y2 para intervenciones terapeuticas. |
| SG158141A1 (en) | 2004-12-13 | 2010-01-29 | Amylin Pharmaceuticals Inc | Pancreatic polypeptide family motifs, polypeptides and methods comprising the same |
| ES2381497T3 (es) | 2005-12-07 | 2012-05-28 | F. Hoffmann-La Roche Ag | Agonistas del receptor del neuropéptido-2 |
| BRPI0807728A2 (pt) | 2007-02-15 | 2012-04-17 | Univ Indiana Res & Tech Corp | co-agonistas de receptor glucagon/glp-1 |
| ATE520714T1 (de) | 2007-06-15 | 2011-09-15 | Zealand Pharma As | Glucagonanaloga |
| JP2011503180A (ja) | 2007-11-14 | 2011-01-27 | アミリン・ファーマシューティカルズ，インコーポレイテッド | 肥満ならびに肥満関連の疾患および障害の処置方法 |
| FR2934058B1 (fr) | 2008-07-15 | 2010-09-24 | Centre Nat Rech Scient | Dispositif de projection interferometrique a trois ouvertures pour produire une tache constituee de structures fines |
| EA020537B1 (ru) | 2008-12-15 | 2014-11-28 | Зилэнд Фарма А/С | Аналоги глюкагона |
| MX2011006314A (es) | 2008-12-15 | 2011-09-22 | Zealand Pharma As | Analogos de glucagon. |
| CA2747155A1 (en) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
| DK2370462T3 (da) | 2008-12-15 | 2014-09-08 | Zealand Pharma As | Glucagon-analoger |
| US9156901B2 (en) | 2009-07-13 | 2015-10-13 | Ditte Riber | Acylated glucagon analogues |
| JP2013505221A (ja) | 2009-09-18 | 2013-02-14 | ノヴォ ノルディスク アー／エス | 長時間作用性ｙ２受容体アゴニスト |
| CN102905722A (zh) * | 2009-11-13 | 2013-01-30 | 诺沃—诺迪斯克有限公司 | 长效y2受体激动剂 |
| UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
| NZ604208A (en) | 2010-06-24 | 2014-10-31 | Zealand Pharma As | Glucagon analogues |
| CA2838884C (en) | 2011-06-10 | 2022-11-29 | Novo Nordisk A/S | Amylin receptor agonists |
| AP2014007797A0 (en) | 2011-12-23 | 2014-07-31 | Boehringer Ingelheim Int | Glucagon analogues |
| CA2872314C (en) | 2012-05-03 | 2021-08-31 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| HK1214829A1 (zh) | 2013-05-02 | 2016-08-05 | Glaxosmithkline Intellectual Property Development Limited | 治疗肽 |
| AR097701A1 (es) | 2013-09-19 | 2016-04-13 | Zealand Pharma As | Análogos de amilina |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| CN119119233A (zh) | 2013-10-17 | 2024-12-13 | 西兰制药公司 | 酰化胰高血糖素类似物 |
| WO2015067716A1 (en) | 2013-11-06 | 2015-05-14 | Zealand Pharma A/S | Glucagon-glp-1-gip triple agonist compounds |
| JP6639389B2 (ja) | 2013-11-14 | 2020-02-05 | キーバイオサイエンス・アクチエンゲゼルシャフト | 疾患および障害を処置するためのカルシトニン模倣体 |
| TWI661835B (zh) | 2013-11-15 | 2019-06-11 | 丹麥商諾佛 儂迪克股份有限公司 | 選擇性ｐｙｙ化合物及其用途 |
| JP6769984B2 (ja) | 2015-03-18 | 2020-10-14 | ジーランド ファーマ アクティーゼルスカブ | アミリン類似体 |
| KR20170137198A (ko) | 2015-04-16 | 2017-12-12 | 질랜드 파마 에이/에스 | 아실화된 글루카곤 유사체 |
| WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| MA43205A (fr) | 2015-06-12 | 2018-09-19 | Novo Nordisk As | Composés pyy sélectifs et leurs utilisations |
| EP3398961B1 (en) | 2015-12-31 | 2022-06-29 | Hanmi Pharm. Co., Ltd. | Triple activator activating glucagon, glp-1 and gip receptor |
| EP3452088A4 (en) | 2016-05-03 | 2020-04-15 | The Scripps Research Institute | TRKB AGONIST ANTIBODIES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES |
| TWI784968B (zh) | 2016-09-09 | 2022-12-01 | 丹麥商西蘭製藥公司 | 澱粉素類似物 |
| JOP20190097A1 (ar) | 2016-10-27 | 2019-04-28 | Janssen Pharmaceutica Nv | الجلوبولينات المناعية واستخداماتها |
| TW201833131A (zh) | 2016-12-02 | 2018-09-16 | 法商賽諾菲公司 | 作為胜肽類ｇｌｐ１／升糖素／ｇｉｐ受體促效劑之新化合物 |
| TW201833132A (zh) | 2016-12-02 | 2018-09-16 | 法商賽諾菲公司 | 作為肽類ｇｌｐ１／升糖素／ｇｉｐ三重受體激動劑之新穎化合物 |
| CN108289005B (zh) | 2017-01-09 | 2021-06-29 | 中兴通讯股份有限公司 | 信令发送、接收方法及装置 |
| GB201704429D0 (en) | 2017-03-21 | 2017-05-03 | Keybioscience Ag | Calcitonin mimetics for treating diseases and disorders |
| US10793634B2 (en) | 2017-06-09 | 2020-10-06 | Boehringer Ingelheim International Gmbh | Anti-TrkB antibodies |
| GB201720188D0 (en) | 2017-12-04 | 2018-01-17 | Imperial Innovations Ltd | Analogues of PYY |
| TWI749381B (zh) * | 2018-11-01 | 2021-12-11 | 美商美國禮來大藥廠 | 蛋白質酪胺酸-酪胺酸類似物及其使用方法 |
| CA3156452A1 (en) | 2019-11-11 | 2021-05-20 | Boehringer Ingelheim International Gmbh | Npy2 receptor agonists |
-
2020
- 2020-11-09 CA CA3156452A patent/CA3156452A1/en active Pending
- 2020-11-09 CN CN202080078045.4A patent/CN114641303A/zh active Pending
- 2020-11-09 PH PH1/2022/551101A patent/PH12022551101A1/en unknown
- 2020-11-09 EP EP20800693.2A patent/EP4058047A1/en active Pending
- 2020-11-09 MX MX2022005661A patent/MX2022005661A/es unknown
- 2020-11-09 KR KR1020227019823A patent/KR20220100925A/ko active Pending
- 2020-11-09 PE PE2022000757A patent/PE20221168A1/es unknown
- 2020-11-09 JO JOP/2022/0110A patent/JOP20220110A1/ar unknown
- 2020-11-09 CR CR20220206A patent/CR20220206A/es unknown
- 2020-11-09 AU AU2020384729A patent/AU2020384729A1/en active Pending
- 2020-11-09 JP JP2022526028A patent/JP2023500895A/ja active Pending
- 2020-11-09 WO PCT/EP2020/081513 patent/WO2021094259A1/en active Application Filing
- 2020-11-10 AR ARP200103125A patent/AR120440A1/es unknown
- 2020-11-10 TW TW109139134A patent/TWI864155B/zh active
- 2020-11-10 US US17/093,680 patent/US20210139548A1/en not_active Abandoned
-
2022
- 2022-04-28 IL IL292601A patent/IL292601A/en unknown
- 2022-05-09 CO CONC2022/0006046A patent/CO2022006046A2/es unknown
- 2022-05-09 DO DO2022000097A patent/DOP2022000097A/es unknown
- 2022-05-10 CL CL2022001227A patent/CL2022001227A1/es unknown
- 2022-05-11 EC ECSENADI202237660A patent/ECSP22037660A/es unknown
- 2022-12-20 US US18/068,641 patent/US12054525B2/en active Active
-
2024
- 2024-06-24 US US18/751,723 patent/US20250002544A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TWI864155B (zh) | 2024-12-01 |
| WO2021094259A1 (en) | 2021-05-20 |
| JP2023500895A (ja) | 2023-01-11 |
| AU2020384729A1 (en) | 2022-04-14 |
| CO2022006046A2 (es) | 2022-05-20 |
| TW202134263A (zh) | 2021-09-16 |
| DOP2022000097A (es) | 2022-06-15 |
| PH12022551101A1 (en) | 2023-11-13 |
| US20230340039A1 (en) | 2023-10-26 |
| US12054525B2 (en) | 2024-08-06 |
| CA3156452A1 (en) | 2021-05-20 |
| EP4058047A1 (en) | 2022-09-21 |
| AR120440A1 (es) | 2022-02-16 |
| JOP20220110A1 (ar) | 2023-01-30 |
| US20250002544A1 (en) | 2025-01-02 |
| CN114641303A (zh) | 2022-06-17 |
| MX2022005661A (es) | 2022-09-07 |
| CL2022001227A1 (es) | 2023-02-03 |
| US20210139548A1 (en) | 2021-05-13 |
| IL292601A (en) | 2022-07-01 |
| CR20220206A (es) | 2022-06-16 |
| KR20220100925A (ko) | 2022-07-18 |
| ECSP22037660A (es) | 2022-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20221168A1 (es) | Agonistas del receptor npy2 | |
| CL2020002796A1 (es) | Derivados de gip y usos de estos | |
| EA201991316A1 (ru) | Конъюгаты, содержащие двойной агонист glp-1/глюкагона, линкер и гиалуроновую кислоту | |
| AR100945A1 (es) | Proteínas de fusión mic-1 y usos de las mismas | |
| MX2020007410A (es) | Formulaciones, composiciones y métodos farmacéuticos de péptido yy. | |
| PE20142332A1 (es) | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas | |
| SA521421873B1 (ar) | نظائر بروتين تيروسين-تيروسين وطرق لاستخدامها | |
| CL2023000357A1 (es) | Agonistas del receptor npy2 solubles | |
| PH12020551118A1 (en) | Modified lipidated relaxin b chain peptides and their therapeutic use | |
| SA521421715B1 (ar) | تركيبات سيماجلوتيد ثابتة واستخداماتها | |
| CL2019003441A1 (es) | Puestos de mic-1 y usos de estos. | |
| PE20210116A1 (es) | Administracion oral de analogos del peptido glp-1 | |
| RU2017112982A (ru) | Композиции иммуногенных/терапевтических гликоконъюгатов и их применения | |
| EA201591338A1 (ru) | Гастроретентивная лекарственная форма секвестранта желчных кислот с замедленным высвобождением для перорального применения | |
| NZ771890A (en) | Il-17a binding peptides and medical uses thereof | |
| BR112019004210A2 (pt) | composição farmacêutica, método e kit para tratamento da deficiência de hormônio do crescimento | |
| MX2020002247A (es) | Derivado de gnrh de conjugado a ácido palmítico de larga duración y composición farmacéutica que lo contiene. | |
| PE20211772A1 (es) | Inmunoterapia con peptidos restringidos a b 08 y una combinacion de peptidos contra el cancer y metodos relacionados | |
| JP2014522414A5 (es) | ||
| EA202090666A1 (ru) | Применение содержащей бензоат композиции для лечения глициновой энцефалопатии | |
| UY38473A (es) | Formulaciones farmacéuticas para una administración subcutánea | |
| EA202191511A1 (ru) | Составы на основе аналога пептида оксинтомодулина | |
| EA202190923A1 (ru) | Аналоги белка тирозин-тирозин и способы их применения | |
| BR112022006297A2 (pt) | Agonistas de receptor de npy2 | |
| ZA202306305B (en) | Pharmaceutical compounds |